Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cedric Happi Mbakam has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Small-molecule inhibitors of proteasome increase CjCas9 protein stability

    by Pouiré Yaméogo, Nathalie Majeau, Cedric Happi Mbakam, Jacques P Tremblay

    The small size of CjCas9 can make easier its vectorization for in vivo gene therapy. However, compared to the SpCas9, the CjCas9 is, in general, less efficient to generate indels in target genes. The factors that affect its efficacity are not yet determined. We observed that the CjCas9 protein expressed in HEK293T cells after transfection of this transgene under a CMV promoter was much lower than the SpCas9 protein in the same conditions. We thus evaluated the effect of proteasome inhibitors on CjCas9 protein stability and its efficiency on FXN gene editing. Western blotting showed that the addition of MG132 or bortezomib, significantly increased CjCas9 protein levels in HEK293T and HeLa cells. Moreover, bortezomib increased the level of CjCas9 protein expressed under promoters weaker than CMV such as CBH or EFS but which are specific for certain tissues. Finally, ddPCR quantification showed that bortezomib treatment enhanced CjCas9 efficiency to delete GAA repeat region of FXN gene in HEK293T cells. The improvement of CjCas9 protein stability would facilitate its used in CRISPR/Cas system.


  • Open Access

    Prime editing optimized RTT permits the correction of the c.8713C>T mutation in DMD gene

    by Cedric Happi Mbakam, Joel Rousseau, Yaoyao Lu, Anne Bigot, Kamel Mamchaoui, Vincent Mouly, Jacques P. Tremblay


  • Open Access

    Improvements of nuclease and nickase gene modification techniques for the treatment of genetic diseases

    by Yaoyao Lu, Cedric Happi Mbakam, Bo Song, Eli Bendavid, Jacques-P. Tremblay

    Advancements in genome editing make possible to exploit the functions of enzymes for efficient DNA modifications with tremendous potential to treat human genetic diseases. Several nuclease genome editing strategies including Meganucleases (MNs), Zinc Finger Nucleases (ZFNs), Transcription Activator-like Effector Nucleases (TALENs) and Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR associated proteins (CRISPR-Cas) have been developed for the correction of genetic mutations. CRISPR-Cas has further been engineered to create nickase genome editing tools including Base editors and Prime editors with much precision and efficacy. In this review, we summarized recent improvements in nuclease and nickase genome editing approaches for the treatment of genetic diseases. We also highlighted some limitations for the translation of these approaches into clinical applications.


  • Open Access

    Prime Editing Permits the Introduction of Specific Mutations in the Gene Responsible for Duchenne Muscular Dystrophy

    by Cédric Happi Mbakam, Joël Rousseau, Guillaume Tremblay, Pouiré Yameogo, Jacques P. Tremblay

    The Prime editing technique derived from the CRISPR/Cas9 discovery permits the modification of selected nucleotides in a specific gene. We used it to insert specific point mutations in exons 9, 20, 35, 43, 55 and 61 of the Duchenne Muscular Dystrophy (DMD) gene coding for the dystrophin protein, which is absent in DMD patients. Up to 11% and 21% desired mutations of the DMD gene in HEK293T cells were obtained with the PRIME Editor 2 (PE2) and PE3, respectively. Three repeated treatments increased the percentage of specific mutations with PE2 to 16%. An additional mutation in the protospacer adjacent motif (PAM) sequence improved the PE3 result to 38% after a single treatment. We also carried out the correction of c.428 G>A point mutation in exon 6 of the DMD gene in a patient myoblast. Myoblast electroporation showed up to 8% and 28% modifications, respectively, for one and three repeated treatments using the PE3 system. The myoblast correction led to dystrophin expression in myotubes detected by Western blot. Thus, prime editing can be used for the correction of point mutations in the DMD gene.


  • Open Access

    Therapeutic Strategies for Dystrophin Replacement in Duchenne Muscular Dystrophy

    by Cedric Happi Mbakam, Gabriel Lamothe, Jacques P. Tremblay

    Duchenne muscular dystrophy (DMD) is an X-linked hereditary disease characterized by progressive muscle wasting due to modifications in the DMD gene (exon deletions, nonsense mutations, intra-exonic insertions or deletions, exon duplications, splice site defects, and deep intronic mutations) that result in a lack of functional dystrophin expression. Many therapeutic approaches have so far been attempted to induce dystrophin expression and improve the patient phenotype. In this manuscript, we describe the relevant updates for some therapeutic strategies for DMD aiming to restore dystrophin expression. We also present and analyze in vitro and in vivo ongoing experimental approaches to treat the disease.


  • CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy

    by Cedric Happi Mbakam, Gabriel Lamothe, Guillaume Tremblay, Jacques P. Tremblay


  • Insertion of the Icelandic Mutation (A673T) by Prime Editing: A Potential Preventive Treatment for Familial and Sporadic Alzheimer's Disease

    by Guillaume Tremblay, Joël Rousseau, Cedric Happi Mbakam, Jacques P. Tremblay

    Alzheimer's disease (AD) is the result of abnormal processing of the amyloid precursor protein (APP) by β-secretase and γ-secretase, which leads to the formation of toxic β-amyloid peptides. The toxic β-amyloid peptides induce neuron death, memory problems, and AD development. Several APP mutations increase the risk of developing early-onset AD. However, the A673T mutation identified in the Icelandic population prevents AD development by reducing the cleavage of APP by β-secretase. In this study, we inserted the A673T mutation in human cells using the CRISPR prime editing (PE) technique. Repeated PE treatments resulted in the insertion of the A673T mutation in up to 49.2% of APP genes when a second nick was induced in the other DNA strand. When the protospacer adjacent motif used for PE was also mutated, up to 68.9% of the APP genes contained the protective A673T mutation. PE is a promising approach to introduce the A673T mutation precisely without mutating nearby nucleotides.


  • Open Access

    Kinetics of CD4+ T-cell recovery amongst HIV load suppressed patients on first-line antiretroviral therapy in Yaoundé, Cameroon

    by Cedric Happi Mbakam, Julius Mbekem Nwobegahay, Cybelle Fodieu Mezajou, Franklin Agueguia Azebaze, Leopold Mbous Nguimbus, Audrey Pamela Ngouambe Ngaleu, Cédric Romuald Yapfa Djomaha, Mureille Maffo, Graeme Brendon Jacobs, Marie Claire Okomo Assoumou, et al.

    HIV infected patients on Antiretroviral Therapy (ART) are exposed to various immunological disorders. Immune reconstitution is one of the most challenging problem linked to morbidity and mortality in HIV patients. This study aimed at evaluating the kinetics of CD4+ T-cell recovery amongst HIV load suppressed patients on first-line ART in Yaoundé, Cameroon. This was a retrospective cohort study performed at the care and treatment units of the Yaoundé University Teaching Hospital and Essos Hospital Center, with viral suppressed patients initiated on ART between March and July 2015. Data were collected using a standard form and analyzed using R.3.6.2 software. A p<0.05 was considered statistically significant for a 95%CI. Of the 499 viral suppressed participants, 32% (n=160) were male and 68% (n=339) female; 33% and 40% had severe and moderate immunodepression at baseline, respectively; 9% and 28% remain respectively on the same immunological state. CD4+ T-cell count increased by 73%, 49% and 29% for patients that started treatment, with CD4+ <150 cells/ml, 150<CD4+<350 cells/ml and 350<CD4+<500 cells/ml, respectively and 14%, 34% and 40% reached a target of 500 cells/ml or more after 4 years of treatment. Elder patients and males were likely to have CD4+ T-cells less than 350 Cells/ml. Approximately 35% of patient started treatment with CD4+ T-cells <350 Cells/ml. CD4+ T-cells increased significantly during 4 years of treatment but, just 29% in average achieved CD4+ ≥ 500 cells/ml. CD4 T-cells recovery represent and important challenge in the immunological monitoring of long-term HIV infected patients on ART.


  • Open Access

    Involvement of CD95 and ligand in CD4+ T-cell and CD8+ T-cell depletion and hepatic cytolysis in patients with chronic viral hepatitis B

    by Franklin S. Azebaze Agueguia, Paul Talla, Marie C. Okomo Assoumou, Graeme B. Jacobs, Cedric H. Mbakam, Elise Guiedem, Martha Tongo Mesembe, Emilia Lyonga, George Mondinde Ikomey

    Background: Chronic viral hepatitis B (HBV) is characterised by progressive hepatocyte destruction and T-cell depletion. The mechanisms of the CD95-CD95 ligand (CD95L) signalling pathway during this chronic disease and the cirrhotic process remains unclear.Objective: We evaluated the involvement of the CD95-CD95L receptor-ligand system in T-cell depletion and hepatic cytolysis in patients with chronic HBV.Methods: This was a cross-sectional study conducted from September to December 2018 at the Yaoundé General Hospital, Cameroon. Four mL of whole blood was collected and analysed. The CD95 and CD95L levels, as well as the CD4+ T-cell and CD8+ T-cell counts, were performed by enzyme-linked immunosorbent assay and flow cytometry.Results: Of the 130 HBV-positive patients, 36 (27.7%) were cirrhotic and 94 (72.3%) were non-cirrhotic. The cirrhotic patients had significantly elevated CD95 (p 0.001) and CD95L (p = 0.001) plasma levels, compared with non-cirrhotic patients. The CD4/CD8 ratios were lower in cirrhotic patients, compared to non-cirrhotic patients (p 0.001). There were statistically significant correlations between CD95 level and CD4+ T-cell counts, between CD95 level and CD8+ T-cell counts, between CD95 level and the CD4/CD8 ratio, between CD95 level and fibrosis score, and between CD95L level and fibrosis score.Conclusion: CD95 and CD95L could be involved in T-cell depletion and hepatic cytolysis during the pathogenesis of chronic HBV and could potentially be used as biomarkers for immunological and hepatic monitoring in patients with chronic HBV.

  • Open Access

    Cytokine levels of interleukin-2 and 7 amongst antiretroviral therapy success and failure HIV patients attending the University Teaching Hospital, Yaoundé, Cameroon

    by George Mondinde Ikomey, Cedric Happi Mbakam, Marie Claire Okomo Assoumou, Jacobs Graeme Brandon, Martha Mesembe, Emilia Lyonga Mbamyah, Edward Murphy, Claude Tayou Tagny

    Immune reconstitution complications (IRC) are major problems faced by HIV treated patients worldwide. Interleukin (IL)-2 and IL-7 play vital roles in peripheral T-cell homeostasis. Our study objective was to measure and compare the blood plasma levels of IL-2 and IL-7 amongst antiretroviral therapy (ART) patients attending the Yaoundé University Teaching Hospital, Cameroon. We performed a cross-sectional study with 296 HIV positive patients enrolled between July 2017 and May 2018 at the Yaoundé University Teaching Hospital. IL-2, IL-7, T-cell profile counts and plasma viral load were measured on whole blood specimens. Data obtained were analyzed using Graph Pad Prism 5.0 and Epi info 7.0 Software. IL-2 and IL-7 plasma concentration levels were higher in patients with ART failure compared to ART success, with a mean ± SD of 19.4±8 and 17.1±6 pg /ml, 35.26±11 and 21.5±5 pg/ml, with p < 0.001 and < 0.001. There was a direct and significant correlation between viral load, IL-2 and IL-7 with p values = 0.028, and 0.020, respectively. There was an association between IL-2, IL-7 and viral load in relation to the duration on treatment (DT), with p values = 0.003 (R2= 0.041, CI= 0.069 – 0.34) ,0.017 (R2= 0.027, CI= -0.30 – 0.030), and 0.001 (R2= 0.048, CI= -0.047–0.76). Considering that limited surrogate markers are available for monitoring immune reconstitution and high associated mortality rates, IL-2 and IL-7 could be a good immunological predictor for ART failure and success in HIV infected individuals. © 2020 International Formulae Group. All rights reserved. Keywords: Homeostasis, Immune reconstitution, Interleukins, ART